Cytosorbents (NASDAQ:CTSO) Stock Passes Above 200-Day Moving Average – Time to Sell?

Cytosorbents Co. (NASDAQ:CTSOGet Free Report)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.99 and traded as high as $1.10. Cytosorbents shares last traded at $1.07, with a volume of 23,276 shares trading hands.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CTSO. Wall Street Zen initiated coverage on Cytosorbents in a report on Wednesday, May 21st. They set a “hold” rating for the company. HC Wainwright restated a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research note on Thursday, May 15th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a report on Thursday, May 15th.

View Our Latest Report on Cytosorbents

Cytosorbents Trading Down 1.8%

The business’s 50-day moving average is $0.96 and its two-hundred day moving average is $0.99. The stock has a market capitalization of $66.99 million, a PE ratio of -2.97 and a beta of 1.05. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Cytosorbents (NASDAQ:CTSOGet Free Report) last posted its earnings results on Wednesday, May 14th. The medical research company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. The business had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.01 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. On average, analysts anticipate that Cytosorbents Co. will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

Several large investors have recently modified their holdings of CTSO. Millennium Management LLC purchased a new stake in Cytosorbents in the 4th quarter valued at $30,000. Goldman Sachs Group Inc. increased its stake in Cytosorbents by 149.2% in the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 37,519 shares during the period. Key Client Fiduciary Advisors LLC raised its holdings in shares of Cytosorbents by 127.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company’s stock valued at $78,000 after buying an additional 43,900 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Cytosorbents by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after buying an additional 8,400 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after buying an additional 16,701 shares during the period. 32.87% of the stock is owned by institutional investors and hedge funds.

Cytosorbents Company Profile

(Get Free Report)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

Featured Stories

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.